New pill targets brain tumor metabolism in early trial
NCT ID NCT06636162
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early phase 1 trial is testing an oral drug called DSP-0390 in 20 people with IDH-mutant gliomas who are scheduled for tumor removal surgery. The goal is to see how much of the drug gets into the brain tumor and blood, and whether it affects cholesterol-related pathways. Participants take the drug for about two weeks before surgery, and tissue and blood samples are collected to measure drug levels and biological changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DSP-0390 (oral drug)
What this could lead to
If successful, this could point toward a new treatment option for IDH-mutant gliomas by targeting cholesterol metabolism.
What could go wrong
This is a very early, small study (20 people) focused on drug levels and safety, not on curing or shrinking tumors. It may not lead to an effective treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA, MALIGNANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact